Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 9, 2014, Pages

  Baert, Filip ^a   Drobne, David ^a   Gils, Ann ^b   Vande Casteele, Niels ^b   Hauenstein, Scott ^c   Singh, Sharat ^c   Lockton, Steve ^c   Rutgeerts, Paul ^a   Vermeire, Séverine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c Prometheus Laboratories Inc   (United States)

Author keywords

Antidrug antibody; Drug holiday; Pharmacokinetics; Remicade

Indexed keywords

AZATHIOPRINE; DRUG ANTIBODY; HYDROCORTISONE; INFLIXIMAB; LEVOCETIRIZINE; METHOTREXATE; ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CROHN DISEASE; DELAYED REACTION; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREGNANCY; REIMBURSEMENT; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; TIME; TREATMENT OUTCOME; YOUNG ADULT; GASTROENTEROLOGY; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; PREDICTION; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906791611     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.01.033     Document Type: Article

References (24)

1. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol 2010, 56:233-243.
2. Chaparro M., Martinez-Montiel P., Van Domselaar M., et al. Intensification of infliximab therapy in Crohn's disease: efficacy and safety. JCrohns Colitis 2012, 6:62-67.
3. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
4. Baert F., Glorieus E., Reenaers C., et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. JCrohns Colitis 2013, 7:154-160.
5. Gisbert J.P., Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
6. Danese S., Fiorino G., Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF therapy. Aliment Pharmacol Ther 2011, 34:1-10.
7. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348:601-608.
8. Baert F., De Vos M., Louis E., et al. Immunogenicity of infliximab: how to handle the problem?. Acta Gastroenterol Belg 2007, 70:163-170.
9. Wang S.L., Ohrmund L., Hauenstein S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. JImmunol Methods 2012, 382:177-188.
10. Vande Casteele N., Gils A., Singh S., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013, 108:962-971.
11. Van de Casteele N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36:765-771.
12. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease. Gastroenterology 2003, 124:917-924.
13. Steenholdt C., Svenson M., Ainsworth M.A., et al. Comparison of techniques for monitoring infliximab bioavailability and immunogenicity in Crohn's disease. Gastroenterology 2012, 142(Suppl 1). S-781.
14. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
15. Vande Casteele N., Ballet V., Van Assche G., et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012, 61:321.
16. Cornillie F., Hanauer S., Diamond R.H., et al. Can clinical, biological or pharmacological markers predict sustained response to infliximab? A retrospective analysis of ACCENT 1. Gut 2011, 60(Suppl 3):A296.
17. Arias M.T., Vande Casteele N., Drobne D., et al. Importance of trough levels and antibodies on the long term treatment efficacy of infliximab therapy in ulcerative colitis. JCrohn Colitis 2012, 6(Suppl 1):S5.
18. Colombel J.F., Sandborn W.J., Allez M., et al. Certolizumab pegol plasma concentrations and endoscopic response and remission in Crohn's disease. Gut 2012, 61(Suppl 3):A81.
19. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
20. Drobne D., Bossuyt P.J., Breynaert C., et al. Infliximab trough levels and CRP during infliximab-immunomodulator combination treatment for Crohn's disease are associated with clinical outcome after immunomodulator withdrawal. Gastroenterology 2011, 140(Suppl 1). S-279.
21. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014, 63:1258-1264.
22. Ben-Horin S., Waterman M., Kopylov U., et al. Addition of an immunomodulator to infliximab therapy eliminates anti-drug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11:444-447.
23. Ordas I., Mould D.R., Feagan B.G., et al. Anti-TNF monoclonal antibodies in IBD: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.
24. Vande Casteele N., Compernolle G., Ballet V., et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab treatment (TAXIT) trial. JCrohns Colitis 2012, 6(Suppl 1). S-6.